Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endoplasmic reticulum membrane; Single-pass type III membrane protein. Golgi apparatus. Golgi apparatus, trans-Golgi network membrane. Melanosome. Note=Also found in small vesicles and tubules dispersed over the entire cytoplasm. A small fraction of the protein is inserted into the membrane in an inverted orientation. Inversion of membrane topology results in the relocalization of the protein from a predominant Golgi/post-Golgi area to the endoplasmic reticulum. Melanoma cells expressing the protein with an inverted membrane topology are more effectively recognized by specific cytolytic T-lymphocytes than those expressing the protein in its native membrane orientation. |
Domain |
PF14991 Protein melan-A |
Function |
Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes. |
Biological Process | - |
Molecular Function | - |
Cellular Component |
GO:0005802 trans-Golgi network GO:0031984 organelle subcompartment GO:0042470 melanosome GO:0048770 pigment granule GO:0098791 Golgi subcompartment |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MLANA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between MLANA and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MLANA in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MLANA in various data sets.
|
Points in the above scatter plot represent the mutation difference of MLANA in various data sets.
|
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MLANA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MLANA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MLANA. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MLANA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MLANA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MLANA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MLANA |
Name | melan-A |
Aliases | MART-1; antigen LB39-AA; antigen SK29-AA; protein Melan-A; Melanoma antigen recognized by T-cells 1 |
Chromosomal Location | 9p24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MLANA collected from DrugBank database. |
There is no record. |